(Q38782016)

6 September 2017

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer (English)

1 reference

6 September 2017

1 reference

Sherry X Yang

1

1 reference

PubMed ID

26995633

6 September 2017

Eric Polley

series ordinal

2

1 reference

PubMed ID

26995633

6 September 2017

Stanley Lipkowitz

series ordinal

3

1 reference

6 September 2017

9 March 2016

1 reference

6 September 2017

Cancer Treatment Reviews

1 reference

6 September 2017

45

1 reference

6 September 2017

87-96

1 reference

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

6 September 2017

1 reference

12 December 2020

Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer

1 reference

12 December 2020

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

1 reference

12 December 2020

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

1 reference

12 December 2020

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

1 reference

12 December 2020

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

1 reference

12 December 2020

Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel

1 reference

12 December 2020

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

1 reference

12 December 2020

Role of AKT isotypes in breast cancer

1 reference

12 December 2020

Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer

1 reference

12 December 2020

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer

1 reference

12 December 2020

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program

1 reference

12 December 2020

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

12 December 2020

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients

1 reference

12 December 2020

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status

1 reference

12 December 2020

PIK3CA mutation associates with improved outcome in breast cancer.

1 reference

12 December 2020

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

1 reference

12 December 2020

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer

1 reference

12 December 2020

Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells

1 reference

12 December 2020

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

12 December 2020

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

1 reference

12 December 2020

Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications

1 reference

12 December 2020

Activation of PI3K/Akt signaling and hormone resistance in breast cancer

1 reference

12 December 2020

PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer?

1 reference

12 December 2020

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.

1 reference

12 December 2020

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

12 December 2020

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

1 reference

12 December 2020

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

12 December 2020

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

1 reference

12 December 2020

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

1 reference

12 December 2020

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

1 reference

12 December 2020

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

12 December 2020

Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.

1 reference

12 December 2020

Estrogen receptor: current understanding of its activation and modulation

1 reference

12 December 2020

Comprehensive molecular portraits of human breast tumours

1 reference

12 December 2020

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

1 reference

12 December 2020

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

1 reference

12 December 2020

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

1 reference

12 December 2020

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

1 reference

12 December 2020

Statistical and practical considerations for clinical evaluation of predictive biomarkers

1 reference

12 December 2020

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

12 December 2020

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

1 reference

12 December 2020

Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones.

1 reference

12 December 2020

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

1 reference

12 December 2020

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

1 reference

12 December 2020

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

1 reference

12 December 2020

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

1 reference

12 December 2020

Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women

1 reference

12 December 2020

Akt kinases in breast cancer and the results of adjuvant therapy

1 reference

12 December 2020

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

1 reference

12 December 2020

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

1 reference

12 December 2020

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

12 December 2020

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

1 reference

12 December 2020

Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.

1 reference

12 December 2020

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

1 reference

12 December 2020

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

12 December 2020

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

12 December 2020

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

12 December 2020

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

12 December 2020

Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview

1 reference

12 December 2020

Mutation of the PIK3CA oncogene in human cancers

1 reference

12 December 2020

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

1 reference

12 December 2020

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

12 December 2020

MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy.

1 reference

12 December 2020

Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate

1 reference

12 December 2020

Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis

1 reference

12 December 2020

PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

1 reference

12 December 2020

Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation

1 reference

12 December 2020

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

1 reference

12 December 2020

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

12 December 2020

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

1 reference

12 December 2020

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

12 December 2020

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

1 reference

12 December 2020

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

1 reference

12 December 2020

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

12 December 2020

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

1 reference

12 December 2020

Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas

1 reference

12 December 2020

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

1 reference

12 December 2020

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.

1 reference

12 December 2020

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

1 reference

12 December 2020

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

1 reference

12 December 2020

Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis

1 reference

12 December 2020

Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate

1 reference

12 December 2020

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

12 December 2020

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

12 December 2020

Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.

1 reference

12 December 2020

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

12 December 2020

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

12 December 2020

PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt

1 reference

12 December 2020

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

12 December 2020

PI3K: downstream AKTion blocks apoptosis

1 reference

12 December 2020

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

12 December 2020

Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.

1 reference

12 December 2020

Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival

1 reference

12 December 2020

Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer

1 reference

12 December 2020

10.1016/J.CTRV.2016.03.004

Identifiers

DOI

1 reference

6 September 2017

0 references

1 reference

PubMed ID

26995633